Filtered By:
Specialty: Hematology
Condition: Pulmonary Thromboembolism
This page shows you your search results in order of relevance. This is page number 7.
Order by Relevance | Date
Total 147 results found since Jan 2013.
Heparin-induced thrombocytopenia and thrombosis in a patient with Covid-19
Covid-19 has significant implications of hematologic systems, including lymphocytopenia, thrombocytopenia, ischemic or hemorrhagic stroke, pulmonary thromboembolism, and myocardial infarction [1,2]. Iwasaki et al. reported that the pathogen of Covid-19, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), can induce immune dysfunction, inflammation, and antibody-dependent enhancement by activating host cells via the Fc γIIa receptor in the same way as SARS-CoV-1 [3].
Source: Thrombosis Research - August 2, 2020 Category: Hematology Authors: Ching-Tai Huang, Shao-Yun Hsu, Ko-Wei Chang, Chung-Guei Huang, Cheng-Ta Yang, Ming-Huei Cheng Tags: Letter to the Editors-in-Chief Source Type: research
A diagnosis of atrial fibrillation is not a predictor for pulmonary embolism
Atrial fibrillation causes stroke by embolization of blood clots from the left atrium. This suggests that it also can cause pulmonary embolism through embolization of thrombi from the right atrium. Our objective was to investigate if atrial fibrillation is an independent risk factor for pulmonary embolism.
Source: Thrombosis Research - August 9, 2020 Category: Hematology Authors: Leif Friberg, Emma Svennberg Tags: Full Length Article Source Type: research
COVID-19 versus HIT hypercoagulability
A striking feature of COVID-19 is the high frequency of thrombosis, particularly in patients who require admission to intensive care unit because of respiratory complications (pneumonia/adult respiratory distress syndrome). The spectrum of thrombotic events is wide, including in situ pulmonary thrombosis, deep-vein thrombosis and associated pulmonary embolism, as well as arterial thrombotic events (stroke, myocardial infarction, limb artery thrombosis). Unusual thrombotic events have also been reported, e.g., cerebral venous sinus thrombosis, mesenteric artery and vein thrombosis.
Source: Thrombosis Research - August 8, 2020 Category: Hematology Authors: Theodore E. Warkentin, Scott Kaatz Tags: Review Article Source Type: research
The effect of race on composite thrombotic events in patients with COVID-19
COVID-19 associated coagulopathy and mortality related to thrombotic complications have been suggested as biological mediators in racial disparities related to COVID-19. We studied the adjusted prevalence of acute ischemic stroke, pulmonary embolism, myocardial infarction, and deep venous thrombosis stratified by race in hospitalized patients in one New York City borough during the local COVID-19 surge. The multi-racial cohort included 4,299 patients hospitalized with COVID-19, 9% of whom were white, 40% black, 41% Hispanic and 10% Asian or other.
Source: Thrombosis Research - December 21, 2020 Category: Hematology Authors: Charles Esenwa, Santiago R. Unda, David J. Altschul, Nikunj K. Patel, Avinash Malaviya, Johanna Seiden, Andrea Lendaris, Khadean Moncrieffe, Daniel L. Labovitz Tags: Letter to the Editors-in-Chief Source Type: research
Recovery from acute kidney injury in patients with pulmonary embolism: A single-center study
Pulmonary embolism (PE) ranks as the third most common cardiovascular death after coronary artery disease and stroke [1] and, the second leading cause of death after cancer among cancer patients [2]. Acute Kidney Injury (AKI), defined as an abrupt decrease in kidney function, is associated with adverse short-term and long-term outcomes even in the case of mild and reversible AKI [3]. One-third of patients with PE develop AKI and are at increased risk for bleeding and mortality compared with patients without AKI [4].
Source: Thrombosis Research - January 14, 2021 Category: Hematology Authors: Martin Murgier, L éa Fouillet, Edouard Ollier, Adel Merah, Nathalie Moulin, Sandrine Accassat, Cécile Duvillard, Elodie De Magalhaes, Patrick Mismetti, Manuel Monreal, Laurent Bertoletti Tags: Letter to the Editors-in-Chief Source Type: research
Pulmonary venous thrombosis in a patient with COVID-19 infection
ConclusionsThrombotic outcomes in the setting of severe COVID 19 pneumonia may include macrovascular venous thromboembolism, microvascular pulmonary vascular thrombosis and arterial thromboembolism. Pulmonary vein, herein described, provides further mechanistic pathway for potential arterial embolic phenomenon.
Source: Journal of Thrombosis and Thrombolysis - January 30, 2021 Category: Hematology Source Type: research
Outcomes in patients with acute pulmonary embolism and patent foramen ovale: Findings from the RIETE registry
An increased risk of ischemic stroke in patients with acute pulmonary embolism (PE) and patent foramen ovale (PFO) was reported but few data exist regarding prognostic outcomes of those patients.
Source: Thrombosis Research - March 7, 2021 Category: Hematology Authors: K. Lacut, E. Le Moigne, F. Couturaud, C. Font, F.J. V ázquez, I. Cañas, J.A. Díaz-Peromingo, A. Gil-Díaz, E. Bucherini, M. Monreal, the RIETE investigators Tags: Full Length Article Source Type: research
Not all patent foramen ovales are alike!
We read with great interest the elegant investigation by Lacut et al., based on RIETE registry, demonstrating that patent foramen ovale (PFO) in patients with acute pulmonary embolism (PE) is under-diagnosed and associated with a higher risk of ischemic stroke compared to those without PFO [1]. to Although the results of this study are interesting and a significant contribution to the management of acute PE, the role of PFO in such study population should be cautiously considered since the study did not provide any anatomical and/or functional PFO characterization.
Source: Thrombosis Research - May 5, 2021 Category: Hematology Authors: Gianluca Rigatelli, Marco Zuin Tags: Letter to the Editors-in-Chief Source Type: research
Pathogenic lipid-binding antiphospholipid antibodies are associated with severity of COVID-19
CONCLUSIONS: COVID-19 patients rapidly expand B1a cells secreting pathogenic lipid-binding aPL with broad thrombotic and inflammatory effects. The association with markers of inflammation and coagulation, clinical severity and mortality suggests a causal role of aPL in COVID-19 associated coagulopathy.PMID:34242469 | DOI:10.1111/jth.15455
Source: Thrombosis and Haemostasis - July 9, 2021 Category: Hematology Authors: Anne Hollerbach Nadine M üller-Calleja Denise Pedrosa Antje Canisius Martin F Sprinzl Tanja Falter Heidi Rossmann Marc Bodenstein Christian Werner Ingo Sagoschen Thomas M ünzel Oliver Schreiner Visvakanth Sivanathan Michael Reuter Johannes Niermann Pete Source Type: research
Extended-Duration Low-intensity Apixaban to Prevent Recurrence in Patients with Provoked Venous Thromboembolism: Design of the HI-PRO Trial
Thromb Haemost. 2021 Sep 16. doi: 10.1055/a-1646-2244. Online ahead of print.ABSTRACTPatients with acute venous thromboembolism (VTE) in the setting of transient provoking factors are typically treated with short-term anticoagulation. However, the risk of recurrence may be increased in the presence of enduring risk factors. In such patients, the optimal duration of treatment remains uncertain. HI-PRO is a single-center, double-blind randomized trial. Patients with deep vein thrombosis (DVT) or pulmonary embolism (PE) following a major provoking factor, including major surgery or major trauma, who completed at least 3 month...
Source: Thrombosis and Haemostasis - September 16, 2021 Category: Hematology Authors: Behnood Bikdeli Heather Hogan Ruth Morrison John Fanikos Umberto Campia Briana Barns Mariana Pfeferman Julia Snyder Candrika Khairani Samuel Z Goldhaber Gregory Piazza Source Type: research
Why Fibrin Biomechanical Properties Matter for Haemostasis and Thrombosis
J Thromb Haemost. 2021 Sep 16. doi: 10.1111/jth.15531. Online ahead of print.ABSTRACTPolymeric fibrin displays unique structural and biomechanical properties that contribute to its essential role of generating blood clots that stem bleeds. The aim of this review is to discuss how the fibrin clot is formed, how protofibrils make up individual fibrin fibres, what the relationship is between the molecular structure and fibrin biomechanical properties, and how fibrin biomechanical properties relate to the risk of thromboembolic disease. Fibrin polymerisation is driven by different types of bonds, including knob-hole interactio...
Source: Thrombosis and Haemostasis - September 16, 2021 Category: Hematology Authors: T ímea Feller Simon D A Connell Robert A S Ari ёns Source Type: research
Reduced-dose intravenous thrombolysis for acute intermediate high-risk pulmonary embolism: Rationale and design of the PEITHO-3 trial
Thromb Haemost. 2021 Sep 24. doi: 10.1055/a-1653-4699. Online ahead of print.ABSTRACTIntermediate high-risk pulmonary embolism (PE) is characterised by right ventricular (RV) dysfunction and elevated circulating cardiac troponin levels despite apparent haemodynamic stability at presentation. In these patients, full-dose systemic thrombolysis reduced the risk of haemodynamic decompensation or death but increased the risk of life-threatening bleeding. Reduced-dose thrombolysis may be capable of improving safety while maintaining reperfusion efficacy. The Pulmonary Embolism International Trial (PEITHO)-3 study (EudraCT 2018-0...
Source: Thrombosis and Haemostasis - September 24, 2021 Category: Hematology Authors: Olivier Sanchez Anais Charles-Nelson Walter Ageno Stefano Barco Harald Binder Gilles Chatellier Daniel Duerschmied Klaus Empen Melanie Ferreira Philippe Girard Menno V Huisman David Jim énez Sandrine Katsahian Matija Kozak Mareike Lankeit Nicolas Menevea Source Type: research
Cardiovascular Mortality after Venous Thromboembolism: A Meta-Analysis of Prospective Cohort Studies
Semin Thromb Hemost DOI: 10.1055/s-0041-1733923Many studies from current literature show that cardiovascular diseases in patients with venous thromboembolism (VTE) are more frequent than in the general population without VTE. However, data summarizing the impact of cardiovascular diseases on mortality of patients with VTE are lacking. In this systematic review and meta-analysis, we aimed to determine the frequency and incidence rate of cardiovascular death in patients with VTE. MEDLINE and EMBASE were searched from January 1, 2000 to February 28, 2021. Eligible studies were observational prospective cohort studies includin...
Source: Seminars in Thrombosis and Hemostasis - October 8, 2021 Category: Hematology Authors: Noumegni, Steve Raoul Grangereau, Thomas Demir, Arzu Bressollette, Luc Couturaud, Francis Hoffmann, Cl ément Tags: Review Article Source Type: research
Platelets and COVID-19
Hamostaseologie. 2021 Oct;41(5):379-385. doi: 10.1055/a-1581-4355. Epub 2021 Oct 25.ABSTRACTIn 2019 first reports about a new human coronavirus emerged, which causes common cold symptoms as well as acute respiratory distress syndrome. The virus was identified as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and severe thrombotic events including deep vein thrombosis, pulmonary embolism, and microthrombi emerged as additional symptoms. Heart failure, myocardial infarction, myocarditis, and stroke have also been observed. As main mediator of thrombus formation, platelets became one of the key aspects in SARS-C...
Source: Hamostaseologie - October 25, 2021 Category: Hematology Authors: Anne-Katrin Rohlfing Dominik Rath Tobias Geisler Meinrad Gawaz Source Type: research
